1. Introduction {#sec1-antioxidants-09-00133}
===============

Ovarian cancer is a highly mortal gynecologic cancer \[[@B1-antioxidants-09-00133],[@B2-antioxidants-09-00133],[@B3-antioxidants-09-00133]\], with the late diagnosis and acquired chemoresistance to the conventional therapy as the major hurdles to cure this disease \[[@B4-antioxidants-09-00133],[@B5-antioxidants-09-00133],[@B6-antioxidants-09-00133]\]. The conventional therapy of ovarian cancer is mainly based on comprehensive oxidative/alkylating drugs such as carboplatin in combination with taxanes \[[@B7-antioxidants-09-00133],[@B8-antioxidants-09-00133],[@B9-antioxidants-09-00133]\]. The platinum drugs induce cell death through two mechanisms: the establishment of adducts of DNA and proteins, and the generation of reactive oxygen species (ROS) \[[@B9-antioxidants-09-00133],[@B10-antioxidants-09-00133]\]. We have previously found that ovarian cancer cells exhibit a great metabolic reliance on cysteine and glutathione (GSH), as these thiols were shown to protect cells under stressful conditions such as hypoxia or carboplatin exposure, hence, also accounting for chemoresistance \[[@B11-antioxidants-09-00133],[@B12-antioxidants-09-00133],[@B13-antioxidants-09-00133]\]. GSH can explain this protective effect given its role as a ROS scavenger and as a pivotal drug detoxifier, allowing cells to evade cell death \[[@B14-antioxidants-09-00133],[@B15-antioxidants-09-00133],[@B16-antioxidants-09-00133],[@B17-antioxidants-09-00133],[@B18-antioxidants-09-00133]\]. We have reported that chemoresistance, supported by high GSH levels, can be abrogated upon the exposure to [l]{.smallcaps}-buthionine sulfoximine ([l]{.smallcaps}-BSO) \[[@B11-antioxidants-09-00133]\], an inhibitor of γ-glutamylcysteine ligase (GCL), the first enzyme catalyzing the synthesis of GSH \[[@B19-antioxidants-09-00133],[@B20-antioxidants-09-00133]\]. However, the systemic administration of [l]{.smallcaps}-BSO is associated to an elevated toxicity, since [l]{.smallcaps}-BSO is an irreversible inhibitor of GCL \[[@B19-antioxidants-09-00133]\]. Therefore, an appropriate approach to revert this systemic toxicity would be the targeted delivery of [l]{.smallcaps}-BSO to cancer cells using a nanoparticles-mediated strategy. In this sense, dendrimers are an outstanding drug delivery platform, and many efforts have been made in the last few years to circumvent their cytotoxicity \[[@B21-antioxidants-09-00133]\], encouraging the fast translation into clinic applications in a near future. In this study, we developed polyurea (PURE) dendrimers, which are a special case of non-toxic \[[@B22-antioxidants-09-00133]\] and non-hemolytic dendrimers up to very high concentrations (circa 50 μM, unpublished data), and that have already been explored in different nanotherapeutic strategies \[[@B23-antioxidants-09-00133],[@B24-antioxidants-09-00133],[@B25-antioxidants-09-00133],[@B26-antioxidants-09-00133]\]. The use of folate-targeted dendrimers is an emergent approach in cancer-targeted chemotherapy \[[@B27-antioxidants-09-00133]\]. As we recently reported \[[@B28-antioxidants-09-00133]\], folate-targeted polyurea dendrimer generation four (PURE~G4~-FA~2~) nanoparticles are a suitable drug delivery system. Of notice, ovarian cancer cells express higher levels of folate receptor α (FA-Rα) than normal cells \[[@B29-antioxidants-09-00133]\] and FA-Rα targeted therapy is an assay commonly tested in in vitro and in vivo models of ovarian cancer \[[@B30-antioxidants-09-00133]\]. In here, we hypothesized that PURE~G4~-FA~2~ encapsulated [l]{.smallcaps}-BSO ([l]{.smallcaps}-BSO\@PURE~G4~-FA~2~) is a suitable strategy to tackle carboplatin resistance, restoring ovarian cancer cells sensitivity to chemotherapy.

2. Materials and Methods {#sec2-antioxidants-09-00133}
========================

2.1. Cell Culture {#sec2dot1-antioxidants-09-00133}
-----------------

Two human ovarian cancer cell lines were used, a serous carcinoma (OSC) cell line (OVCAR3-HTB-161™) and a clear cell carcinoma (OCCC) cell line (ES2-CRL-1978™). In order to analyze the effect of nanoparticles in squamous cells, since ovarian cancer metastasizes preferentially to peritoneum, an immortalized squamous epithelium cell line (HaCaT-PCS-200-011™) was also tested. All the cell lines were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA) and were cultured in Dulbecco's Modified Eagel Medium (DMEM; 41965-039, Gibco, Life Technologies; Massachusetts, MA, USA). All culture media were supplemented with 10% fetal bovine serum (FBS; S 0615, Merck; Darmstadt, Germany), 1% Antibiotic-Antimycotic (AA; P06-07300, PAN Biotech; Aidenbach, Germany) and 50 µg/mL gentamicin (15750-060, Gibco, Life Technologies; Massachusetts, MA, USA). Cells were maintained in a humidified environment of 5% CO~2~ at 37 °C, until reaching approximately 75[--]{.smallcaps}100% optical confluence. Cells were detached with 0.05% Trypsin-EDTA (25300-054, Invitrogen, Thermo Fisher Scientific; Massachusetts, MA, USA) at room temperature (RT) for approximately 5 min, and split to new plates according to the experimental procedures.

2.2. Folate Receptor α (FA-Rα) Immunofluorescence {#sec2dot2-antioxidants-09-00133}
-------------------------------------------------

Sections of 4% paraformaldehyde fixed and paraffin embedded cells (cyto-blocks) were used, after deparaffinization in xylol and re-hydration in a sequence of 5 min incubations in 100%, 70% and 40% ethanol, followed by 10 min in water. Slides were then incubated with the mouse-anti-human FA-Rα (IPI3005G10, BioCare Medical; Pacheco, CA, USA) for 3 h at RT; followed by incubation with the rabbit-anti-mouse Alexa Fluor^®^ 488-conjugated secondary antibody (A-28175, Invitrogen; Massachusetts, MA, USA), 1 h, in the dark, at RT. Slides were mounted in VECTASHIELD media containing DAPI (4′-6-diamidino-2-phenylindole) to counterstain cell nuclei in blue (H-1200, Vector Labs; Burlingame, CA, USA). The analysis was performed by standard fluorescence microscopy in an Axio Imager.Z1 microscope (Zeiss, Oberkochen, Germany). Images were acquired and processed with *CytoVision* software (Leica, Wetzlar, Germany).

2.3. [l]{.smallcaps}-BSO and FL Encapsulation {#sec2dot3-antioxidants-09-00133}
---------------------------------------------

Polyurea (PURE) dendrimers were synthesized following our supercritical-assisted polymerization methodology \[[@B22-antioxidants-09-00133]\]. FA-NHS and PURE~G4~-FA~2~ were synthesized following our reported protocol \[[@B31-antioxidants-09-00133]\]. All chemicals and solvents were used as received without further purification. Folic acid (FA) and *N*,*N*-dicyclohexylcarbodiimide (DCC; A10973) (99% purity) were obtained from Alfa Aesar (Kandel, Germany). Fluorescein (FL; F7505), Triethylamine (TEA; 471283) (≥99.5% purity), *N*-hydroxysuccinimide (NHS; 130672) (98% Purity) and L-buthionine sulfoximine ([l]{.smallcaps}-BSO: B2515) (≥97% purity) were obtained from Sigma-Aldrich (Darmstadt, Germany).

The encapsulation of FL in PURE~G4~-FA~2~ (FL\@PURE~G4~-FA~2~) followed the same methodology used for L-BSO encapsulation \[[@B31-antioxidants-09-00133]\]. Typically, in a vial, FL (0.0131 mmol, 5.3 mg) was dissolved in 1 mL of distilled water. To this solution, the folate-target dendrimer (PURE~G4~-FA~2~) (6.46 µmol, 56.6 mg) was added. The mixture was then left overnight at RT, in the dark, and under stirring. After this period, the product was purified by dialysis (MWCO 100--500 Da) and characterized by ^1^H NMR.

2.4. Confirmation of Cellular Internalization of Nanoparticles by Flow Cytometry {#sec2dot4-antioxidants-09-00133}
--------------------------------------------------------------------------------

Cells (1 × 10^5^ cells/well) were cultured overnight on 24-well plates and then incubated with several concentrations of FL\@PURE~G4~-FA~2~ (0.001--0.120 µM) for 24 h. Only viable adherent cells were collected for the analysis. Cells were then washed with PBS (1×) and detached with trypsin-EDTA. After collection to 1.5 mL Eppendorfs, cells were harvested by centrifugation at 255× *g* for 3 min and washed twice with PBS (1×). Afterwards, cells were suspended in 200 µL of PBS (1×) and samples were analyzed by flow cytometry (FACScalibur--Becton Dickinson; New Jersey, NJ, USA). Sample data was analyzed using *FlowJo* 8.7 software (<https://www.flowjo.com>). The assay was performed at least in three biological replicates.

2.5. Confirmation of Cellular Internalization of Nanoparticles by Fluorescence Microscopy {#sec2dot5-antioxidants-09-00133}
-----------------------------------------------------------------------------------------

The cell lines OVCAR3, ES2 and HaCaT were cultured on glass slides coated with 0.2% gelatine and then incubated with free FL or FL\@PURE~G4~-FA~2,~ for 8 and 24 h. After incubation, cells were fixed in 2% paraformaldehyde for 15 min at RT and washed with PBS (1×). The slides were mounted in VECTASHIELD media with DAPI and examined by standard fluorescence microscopy using an Axio Imager.Z1 microscope. The images were acquired with the *CytoVision* software. The assay was performed at least in three biological replicates.

2.6. Cell Death Analysis by Flow Cytometry {#sec2dot6-antioxidants-09-00133}
------------------------------------------

The cells (1 × 10^5^ cells/well) were seeded in 24-well plates and cultured overnight in control conditions. The effect of different concentrations of free [l]{.smallcaps}-BSO (between 0.05 and 120 mM) and [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ (between 3 and 2522 µM) in cell viability was tested for 24 h of exposure. To evaluate the sensitization effect of L-BSO to carboplatin, OVCAR3 cells were exposed to the previous culture conditions combined with carboplatin (25 μg/mL).

After experimental conditions, the detached cells in supernatants were collected, and adherent cells were harvested with 0.05% Trypsin-EDTA. Cells in the supernatant and trypsinized cells were harvested together by centrifugation, 255× *g* for 2 min. Cells were stained with 0.5 μL annexin V-fluorescein (FITC)-(640906, BioLegend, San Diego, CA, USA), in 1× annexin V binding buffer (10 mM HEPES---pH 7.4, 150 mM NaCl, 2.5 mM CaCl~2~, prepared in 1× PBS---pH 7.4), and incubated at RT, in the dark, for 15 min. Samples were resuspended in 200 μL PBS (1×) plus 1% BSA and centrifuged at 255× *g* for 2 min. Cells were resuspended in 200 μL of annexin V binding buffer 1× and 2.5 μL of propidium iodide (PI, 50 μg/mL; P4170, Sigma-Aldrich; Darmstadt, Germany) was added 5 min prior to analysis. Afterwards, samples were analyzed by flow cytometry (FACScalibur--Becton Dickinson; Franklin Lakes, NJ, USA). Data were analyzed using *FlowJo* 8.7 software (<https://www.flowjo.com>). The assay was performed at least in three biological replicates.

2.7. Statistical Analysis {#sec2dot7-antioxidants-09-00133}
-------------------------

Statistical analyses were performed in *GraphPad Prism* 7.0 software ([www.graphpad.com](www.graphpad.com)). Data is presented as mean ± SD. Assays were performed with at least three biological replicates. For comparisons of two groups, two-tailed unpaired *t*-test was used. To compare more than two groups, one-way and two-way analysis of variance (ANOVA) with Dunnets multiple-comparisons test were used. Statistical significance was established at *p* \< 0.05; \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\* *p* \< 0.0001.

3. Results {#sec3-antioxidants-09-00133}
==========

3.1. Ovarian Cancer Cells Internalize PURE~G4~-FA~2~ Nanoparticles in a Dose Dependent Manner {#sec3dot1-antioxidants-09-00133}
---------------------------------------------------------------------------------------------

The expression of FA-Rα was confirmed in ovarian cancer (ES2 and OVCAR3) and squamous non-cancer (HaCaT) cell lines. As seen, HaCaT cell are negative for FA-Rα, whereas ES2 and OVCAR3 cells express FA-Rα ([Figure 1](#antioxidants-09-00133-f001){ref-type="fig"}A). In order to validate the specificity of the internalization of PURE~G4~-FA~2~ by ovarian cancer cells, we tested fluorescein loaded PURE~G4~-FA~2~ (FL\@PURE~G4~-FA~2~) prior to test L-BSO\@PURE~G4~-FA~2~. By flow cytometry and fluorescence microscopy, we verified that FL is delivered in a dose dependent manner to both ES2 and OVCAR3 cell lines ([Figure 1](#antioxidants-09-00133-f001){ref-type="fig"}). In HaCaT cells, the internalization of fluorescein was only verified at the highest concentration (1 µM) of FL\@PURE~G4~-FA~2~, after 8 and 24 h ([Figure 1](#antioxidants-09-00133-f001){ref-type="fig"}C,D). This observation supports the affinity of FL\@PURE~G4~-FA~2~ to ovarian cancer cells.

3.2. [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ is More Effective in Inducing Cell Death in Ovarian Cancer Cells than Free [l]{.smallcaps}-BSO {#sec3dot2-antioxidants-09-00133}
---------------------------------------------------------------------------------------------------------------------------------------

The efficacy of inducing cell death by free and encapsulated [l]{.smallcaps}-BSO was tested in ovarian cancer cells, in order to verify the advantages of using a [l]{.smallcaps}-BSO targeted delivery. In ovarian cancer cells, the concentration needed to reach 50% of the maximum cytotoxic effect (EC~50~) was higher in free L-BSO than in [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~, indicating a more effective delivery of [l]{.smallcaps}-BSO by the [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ nanoformulation in comparison to free [l]{.smallcaps}-BSO applied directly to the culture media ([Figure 2](#antioxidants-09-00133-f002){ref-type="fig"} and [Figure 3](#antioxidants-09-00133-f003){ref-type="fig"}). The EC~50~ of L-BSO\@PURE~G4~-FA~2~ was 22-fold (ES2) and 81-fold (OVCAR3) lower than the EC~50~ of free [l]{.smallcaps}-BSO ([Figure 2](#antioxidants-09-00133-f002){ref-type="fig"}C,D and [Figure 3](#antioxidants-09-00133-f003){ref-type="fig"}C,D). Furthermore, ES2 cells revealed to be more resistant to the [l]{.smallcaps}-BSO effect than OVCAR3, given the higher EC~50~ for L-BSO\@PURE~G4~-FA~2~ and [l]{.smallcaps}-BSO in this cell line compared to OVCAR3 ([Figure 2](#antioxidants-09-00133-f002){ref-type="fig"}C,D and [Figure 3](#antioxidants-09-00133-f003){ref-type="fig"}C,D).

3.3. [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ Is More Cytotoxic to Ovarian Cancer Cells than to Non-Cancer Squamous Cells {#sec3dot3-antioxidants-09-00133}
--------------------------------------------------------------------------------------------------------------------

[l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ was also tested in non-cancer squamous cells, as an attempt to address the effect in the peritoneal squamous cells, trying to anticipate a future therapy applied by intra-abdominal infusion. Thus, the cell death levels in HaCaT cells were evaluated upon exposure to [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~, and no differences were observed between cells exposed to different concentrations of [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ ([Figure 4](#antioxidants-09-00133-f004){ref-type="fig"}). Interestingly, the highest concentration tested (1000 µM) induced about 10% of cell death in squamous cells, whereas the same concentration induced more than 40% of cell death in ovarian cancer cells ([Figure 3](#antioxidants-09-00133-f003){ref-type="fig"}A,B and [Figure 4](#antioxidants-09-00133-f004){ref-type="fig"}). This result supports that [l]{.smallcaps}-BSO targeted delivery can be a good strategy to treat ovarian cancer without strongly affecting non-cancer cells, at least in a re-sensitizing therapeutic protocol to overcome resistance to platinum salts.

3.4. [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ Is Effective in Increasing the Sensitivity of Ovarian Cancer Cells to Carboplatin {#sec3dot4-antioxidants-09-00133}
--------------------------------------------------------------------------------------------------------------------------

To validate our re-sensitizing approach, the OVCAR3 ovarian cancer cell line was exposed to increasing concentrations of L-BSO\@PURE~G4~-FA~2~ separately or combined with carboplatin. Overall, [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ exposure improved the cytotoxic effect of carboplatin. Furthermore, [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ by itself increased cell death, showing again the reliance of ovarian cancer cells on GSH bioavailability ([Figure 5](#antioxidants-09-00133-f005){ref-type="fig"}). However, the highest concentrations of [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ did not improve carboplatin cytotoxicity, which can be related to the threshold of cell capacity of internalizing nanoparticles.

4. Discussion {#sec4-antioxidants-09-00133}
=============

Acquired chemoresistance is a critical issue in oncology and ovarian cancer is a paradigm of this matter. Therefore, the development of strategies to overcome chemoresistance is required for a more effective treatment of ovarian cancer \[[@B8-antioxidants-09-00133],[@B15-antioxidants-09-00133],[@B32-antioxidants-09-00133],[@B33-antioxidants-09-00133]\]. Following our insights on ovarian cancer metabolic remodeling and therapy response \[[@B11-antioxidants-09-00133],[@B12-antioxidants-09-00133],[@B13-antioxidants-09-00133]\], we posited that a FA-Rα-targeted delivery of [l]{.smallcaps}-BSO can be a promising strategy to revoke resistance to carboplatin ([Figure 6](#antioxidants-09-00133-f006){ref-type="fig"}).

We have previously shown the efficacy of PURE~G4~-FA~2~ nanoparticles as a vehicle to deliver a cytotoxic selenium--chrysin compound to ovarian cancer cells \[[@B28-antioxidants-09-00133]\]. In this study, we have shown the efficacy of those nanoparticles as a vehicle to delivery also [l]{.smallcaps}-BSO to ovarian cancer cells. By using fluorescein loaded PURE~G4~-FA~2~, we verified that ovarian cancer cells are more competent in the internalization of these nanoparticles when compared to non-cancer cells. The observed fluorescein uptake by non-cancer squamous cells at the highest tested concentration can be explained by the use of static cultures and by the fact that after 24 h some particles can adsorb to the cells in a nonspecific way. Nevertheless, our results confirmed that the high levels of FA-Rα expression by cancer cells \[[@B29-antioxidants-09-00133]\] can be explored as a way to reduce the effect of [l]{.smallcaps}-BSO in non-cancerous cells. Indeed, this fact allows a preservative systemic therapeutic approach, since [l]{.smallcaps}-BSO also induces GSH depletion \[[@B34-antioxidants-09-00133],[@B35-antioxidants-09-00133]\] in normal cells, thus, rendering L-BSO otherwise too toxic for therapy. In the early 1990s, L-BSO was used as a drug to treat cancer \[[@B36-antioxidants-09-00133],[@B37-antioxidants-09-00133]\], but its adverse effects were so severe that its use was promptly interrupted. However, more recently, L-BSO has regained attention, and several studies reported the use of this compound in cancer preclinical models \[[@B38-antioxidants-09-00133],[@B39-antioxidants-09-00133],[@B40-antioxidants-09-00133],[@B41-antioxidants-09-00133],[@B42-antioxidants-09-00133]\].

Prior to this study, we demonstrated that free [l]{.smallcaps}-BSO efficiently diminishes GSH bioavailability, impairing resistance to carboplatin \[[@B11-antioxidants-09-00133]\]. Importantly, this effect of L-BSO was also observed in an in vivo model of ovarian cancer, reducing significantly subcutaneous tumor size and GSH levels, as well as peritoneal dissemination \[[@B11-antioxidants-09-00133]\]. In the present study, we verified that a [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ nanoformulation ([Figure 7](#antioxidants-09-00133-f007){ref-type="fig"}) is more effective in inducing ovarian cancer cells death than free [l]{.smallcaps}-BSO; and that ovarian cancer cells are more sensitive to [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ than non-cancer squamous cells (HaCaT), reinforcing a putative therapy mediated by abdominal infusion.

Our previous studies suggested a stronger dependence of ES2 cells on GSH turnover compared with OVCAR3 cells \[[@B12-antioxidants-09-00133],[@B13-antioxidants-09-00133]\], which was also evidenced in this study, as higher EC~50~ of free [l]{.smallcaps}-BSO and [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ were determined for ES2 compared with OVCAR3 cells. Furthermore, concerning resistance to carboplatin, we have reported that upon carboplatin exposure ES2 produce higher levels of GSH \[[@B11-antioxidants-09-00133]\] together with an accelerated GSH turnover, compared with OVCAR3 \[[@B28-antioxidants-09-00133]\]. Therefore, our greatest achievements in this study were the effective use of [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ nanoparticles to the specific targeting of malignant cells, decreasing the harmful effects of [l]{.smallcaps}-BSO in non-malignant cells, and the similar effective targeting of ovarian cancer cells with different levels of chemoresistance. Together, our study supports the use of [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ nanoparticles as a powerful strategy for ovarian cancer treatment.

5. Conclusions {#sec5-antioxidants-09-00133}
==============

More validation studies, namely *in vivo* assays, aiming to evaluate the systemic cytotoxic effect of [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~, are needed. Nevertheless, our study points out this new nanoformulation as a way of avoiding [l]{.smallcaps}-BSO systemic toxicity, and as a tool to abolish cancer cells resistance to carboplatin or putatively to other alkylating/oxidative drugs. In the future, this approach may be applied to other chemoresistant cancers.
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###### 

Ovarian cancer cells internalize FL\@PURE~G4~-FA~2~ nanoparticles in a dose dependent manner. The expression of folate receptor α (FA-Rα) was evaluated by immunofluorescence in HaCaT, ES2 and OVCAR3 cells (**A**). Ovarian cancer cells (OVCAR3 and ES2) were exposed to different concentrations of PURE~G4~-FA~2~ nanoparticles loaded with fluorescein (FL\@PURE~G4~-FA~2~) and the cellular internalization was confirmed by: (**B**) FL fluorescence detected by flow cytometry (after 24 h of incubation); and by fluorescence microscopy (**C**) after 8 h and (**D**) 24 h of incubation. HaCaT cells were used as a control in fluorescence microscopy. In immunofluorescence, nuclei were DAPI (4′,6-diamidino-2-phenylindole) counterstained. Results are shown as mean ± SD. \*\* *p* ≤ 0.01  \*\*\*\* *p* ≤ 0.0001.
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![Free L-BSO induces cell death in ovarian cancer cells in a dose dependent manner in a mM scale. Ovarian cancer cells (OVCAR3 and ES2) were exposed to different concentrations of L-BSO and cell death was determined by flow cytometry using annexin V-FITC and propidium iodide (PI) staining. Cell death percentage related to ES2 cells (**A**) and OVCAR3 cells (**B**) is presented. The concentration of L-BSO needed to reach 50% of the maximum cytotoxic effect (EC~50~) was also calculated: (**C**) EC~50~ related to ES2 cells and (**D**) EC~50~ related to OVCAR3 cells. Results are shown as mean ± SD.  \* *p* ≤ 0.05 \*\*\* *p* ≤ 0.001 \*\*\*\* *p* ≤ 0.0001.](antioxidants-09-00133-g002){#antioxidants-09-00133-f002}

![L-BSO\@PURE~G4~-FA~2~ induces cell death in ovarian cancer cells in a dose dependent manner in a µM scale. Ovarian cancer cells (OVCAR3 and ES2) were exposed to different concentrations of L-BSO loaded into PURE~G4~-FA~2~ nanoparticles (L-BSO\@PURE~G4~-FA~2~) and cell death was determined by flow cytometry using annexin V-FITC and propidium iodide (PI) staining. Cell death percentage related to ES2 cells (**A**) and OVCAR3 cells (**B**) is presented. The concentration of L-BSO\@PURE~G4~-FA~2~ needed to reach 50% of the maximum cytotoxic effect (EC~50~) was also calculated: (**C**) EC~50~ related to ES2 cells and (**D**) EC~50~ related to OVCAR3 cells. Results are shown as mean ± SD.  \* *p* ≤ 0.05, \*\*\*\* *p* ≤ 0.0001.](antioxidants-09-00133-g003){#antioxidants-09-00133-f003}

![L-BSO\@PURE~G4~-FA~2~ does not induce cell death in non-cancer squamous cells (HaCaT). HaCaT cells were exposed to different concentrations of [l]{.smallcaps}-BSO loaded into PURE~G4~-FA~2~ nanoparticles (L-BSO\@PURE~G4~-FA~2~) and cell death percentage was determined by flow cytometry using annexin V-FITC and propidium iodide (PI) staining. Results are shown as mean ± SD.](antioxidants-09-00133-g004){#antioxidants-09-00133-f004}

![L-BSO\@PURE~G4~-FA~2~ sensitizes ovarian cancer cells to carboplatin toxicity. Ovarian cancer cells (OVCAR3) were exposed to increased concentrations of L-BSO\@PURE~G4~-FA~2~ with and without carboplatin (25 µg/mL). Cell death was determined by flow cytometry using annexin V-FITC and propidium iodide (PI) staining. Results are shown as mean ± SD. \* *p* ≤ 0.05 \*\*\*\* *p* ≤ 0.0001.](antioxidants-09-00133-g005){#antioxidants-09-00133-f005}

![Rational of [l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ sensitization to carboplatin toxicity in chemoresistant cancer cells. Cancer cells presenting a high glutathione (GSH) bioavailability are commonly resistant to platinum salts (Pt) toxicity, since GSH is a reactive oxygen species (ROS) scavenger and a xenobiotic detoxifying system. [l]{.smallcaps}-Buthionine sulfoximine ([l]{.smallcaps}-BSO) is an irreversible inhibitor of α-glutamylcysteine ligase (GCL; which has catalytic and modulator subunits, GCLC and GCLM) responsible for GSH synthesis. The targeted delivery of L-BSO in folate-functionalized polyurea dendrimer generation four (PURE~G4~-FA~2~) nanoparticles, taking advantage of the increased expression of FA-Rα in cancer cells, will be efficiently internalized, inhibiting the synthesis of GSH. Therefore, carboplatin will act through its mechanisms of action, ROS generation and adducts formation, culminating in cancer cells death.](antioxidants-09-00133-g006){#antioxidants-09-00133-f006}

![[l]{.smallcaps}-BSO\@PURE~G4~-FA~2~ nanoformulation. Chemical (**A**) and cartoon (**B**) representation of the nanoformulation. L-BSO (green color) is encapsulated in a folate-targeted (orange color) generation four polyurea dendrimer (PURE~G4~-FA~2~).](antioxidants-09-00133-g007){#antioxidants-09-00133-f007}
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